Cross-border rare disease advocacy: Preethi Krishnaraj interviews Harsha Rajasimha
Source: The Company of Biologists Rare diseases affect only a few people in a given population but, collectively, they impact over 400 million people globally
Source: The Company of Biologists Rare diseases affect only a few people in a given population but, collectively, they impact over 400 million people globally
Source: Polite On Society Greetings, everyone. Diversity in medicine in today’s society is important. This week, we hear from Dr. Harsha Rajasimha, Ph.D., Founder and
Source: PRWeb The Food and Drug Administration has approved 16 new gene therapies to date, but for most people around the world, these expensive treatments
Source: PRWeb The cost of patients dropping out of clinical trials continues to be a major problem for the development of new drugs and treatments
Partnering for Success: the Pioneers of Affordable CAR-T Cell/Gene Therapy for Leukemias and Lymphomas. ImmunoAct ImmunoACT is pioneering the first affordable cell and gene therapies
Connect rare disease patients of Indian diaspora everywhere with information, resources, experts, diagnostics, treatment options, and clinical trials. Customer: Indo US RARE Indo US Organization
Health outcomes and biomarkers data collection for persons with neurodevelopmental disorders to accelerate treatment options Customer: COMBINEDBrain The Consortium for Outcome Measures and Biomarkers for
Remote Video eConsent for a Biospecimen Collection Study with Pediatric and Maternal Patients Customer: Childrens National Hospital #5 childrens hospital in the United States serving
Patient registry for muscular dystrophies to accelerate #Genetherapy development Customer: Cure Rare Disease curerd.org is on a mission to research and develop cost-effective, lifesaving long-term therapies
Source: PRWeb Dr. Harsha Rajasimha, Founder and CEO of Jeeva Trials, highlights the importance and value of Investigator-Initiated Trials (IITs) in gathering real-world data on
Jeeva Clinical Trials Inc.